Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up – Here’s Why

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price gapped up prior to trading on Friday . The stock had previously closed at $13.69, but opened at $14.95. Pulse Biosciences shares last traded at $18.3250, with a volume of 69,806 shares changing hands.

Wall Street Analysts Forecast Growth

PLSE has been the subject of a number of recent research reports. Mizuho set a $30.00 price objective on Pulse Biosciences in a research report on Friday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $26.00.

Pulse Biosciences Stock Up 40.1%

The firm has a market cap of $1.30 billion, a P/E ratio of -16.98 and a beta of 1.77. The firm’s 50-day moving average price is $14.15 and its 200 day moving average price is $15.42.

Pulse Biosciences (NASDAQ:PLSE) last announced its earnings results on Wednesday, November 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.02.

Institutional Trading of Pulse Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets increased its holdings in Pulse Biosciences by 63.6% in the second quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Pulse Biosciences by 275.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock valued at $44,000 after purchasing an additional 2,156 shares during the period. Russell Investments Group Ltd. grew its position in Pulse Biosciences by 44.0% during the third quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after buying an additional 1,372 shares in the last quarter. KLP Kapitalforvaltning AS grew its holdings in shares of Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after purchasing an additional 3,400 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in Pulse Biosciences by 184.5% during the second quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock worth $134,000 after buying an additional 5,748 shares in the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.